Bremelanotide
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It was derived from Melanotan II but modified to reduce melanogenic (tanning) effects while retaining sexual function enhancement. PT-141 acts centrally in the hypothalamus through MC3R and MC4R activation, enhancing sexual desire and arousal through neural pathways rather than vascular mechanisms (unlike PDE5 inhibitors). It is used as-needed rather than daily.
Starting dose. 1.75 mg — FDA-approved dose
Take 45-60 minutes before anticipated activity. As-needed dosing. Nausea is common - consider anti-nausea medication. Max 1 dose per 24 hours, max 8 per month.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
PT-141 activates MC3R and MC4R in the hypothalamus, enhancing sexual desire through central dopaminergic and oxytocinergic pathways. Unlike PDE5 inhibitors (Viagra, Cialis) which act on vascular smooth muscle, PT-141 acts on the brain to increase desire and arousal. This central mechanism means it can address desire-based dysfunction, not just erectile mechanics.
45-60 min: Onset of sexual desire enhancement.
2-4 hours: Peak effects.
4-8 hours: Effects wane. Single-use per 24hr.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Bremelanotide is a synthetic peptide melanocortin analog of alpha-melanocyte-stimulating hormone that is an agonist at melanocortin receptors MC3R and MC4R.
Bremelanotide is a synthetic peptide melanocortin analog of alpha-melanocyte-stimulating hormone that is an agonist at melanocortin receptors MC3R and MC4R.
Evidence scope. Human premenopausal sexual-arousal-disorder study; mechanistic statement, not the current subcutaneous 1.75 mg regimen.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 1.75 mg (FDA-approved dose) via SubQ injection, As-needed, at least 45 min before activity. No checked live PubMed abstract supported this complete molecule/formulation/route/dose/frequency combination.
Primary safety claim: Nausea (40% in clinical trials). No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.
Central-acting sexual function
Confirmed. FDA-approved. Works on brain desire pathways, not vascular mechanics. Addresses a different aspect of sexual dysfunction than PDE5 inhibitors.
Confirmed. Modified to reduce tanning while retaining sexual function. Some tanning still possible with repeated use.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
SubQ
Sexual desire enhancement per single dose
Hepatic metabolism and renal excretion
Storage. Standard BAC water 2-8C. 28 days.
FDA-approved as Vyleesi for HSDD in premenopausal women. Off-label male use. WADA not specifically listed.
Put it to work
Open PT-141 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open PT-141 in the app →Go deeper
The complete PT-141 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.